La pêche artisanale dans le bassin de l'Adour: richesses d'hier, secousses d'aujourd'hui, visions pour demain

La pesca artesanal en el Adour, con mil años de historia por lo menos, en una forma organizada, ha conocido, a través de las edades, diversas mutaciones. El siglo XX ha visto acelerarse estos cambios (tecnológicos, reglamentarios, sociales, ecológicos, económicos y culturales). Imaginar su futuro, en el marco socioeconómico y medioambiental del Adour, plantea muchas preguntas. ¿Nuevas mutaciones en perspectiva?Aturriko artisau arrantzak, era antolatuan gutxienez mila urteko historia duenak, hainbat eraldaketa izan ditu, urteak joan urteak etorri. XX. mendean azkartu egin dira aldaketa horiek (tenologikoak, araudikoak, gizarte mailakoak, ekologikoak, ekonomikoak eta kulturalak). Arrantza horren etorkizuna? Aturriko esparru sozioekonomikoan eta ingurugiroan? asmatzeak hainbat galdera sortzen ditu. Beste zenbait aldaketa gertatzear?La pêche artisanale dans l'Adour, avec au moins mille ans d'histoire sous une forme organisée, atraversé, au cours des âges, diverses mutations. Le XXe siècle a vu ces changements (technologiques, réglementaires, sociaux, écologiques, économiques et culturels) s'accélérer. Imaginer son futur, dans le cadre socio-économique et environnemental de l'Adour, soulève de profondes questions. De nouvelles mutations en perspective?Artisan-style fishing in the Adour, with at least a thousand-year history behind it in an organised manner, has experienced various mutations through the ages. The 20th century has witnessed how such changes (technological, regulatory, social, ecological, economic and cultural) have become more frequent. To imagine the future of this type of fishing, within the socio-economic and environmental framework of the Adour, is quite a challenge. Are there new mutations in perspective

Las bibliotecas especializadas y los centros de documentación: situación en el sistema bibliotecario catalán y líneas de futuro

La situació de les biblioteques especialitzades i dels centres de documentació a Catalunya és difícil de definir, ja que hi ha un important desconeixement de quins centres pertanyen a aquesta categoria i de quines són les seves característiques. És una tipologia de centres sobre la qual no s'ha fet una acció institucional com la que va portar a organitzar el sistema de lectura pública o les biblioteques universitàries. Aquesta quantitat indeterminada de centres, de diverses titularitats públiques i privades, tenen un origen, una història, uns fons, uns serveis, uns usuaris i uns objectius molt diferents. El repte que se'ls presenta és la integració plena al sistema bibliotecari de Catalunya i, per això, és necessari planificar accions conjuntes i establir les directrius que els facilitin assolir els objectius comuns al sistema bibliotecari.It's not easy to define the situation of special libraries and documentation centers in Catalonia, because it's not clearly defined which centers belong to this category and their main features. Unlike public or university libraries, for this kind of centers there has never been an institutional action, in order to organize them as a whole system. These undetermined number of centers, both public and private, have diferent origin, history, services, users and goals. They have to face up to the challenge of their full integration within the Catalan library system and its common goals; in order to achieve this it is necessaryto plan joint actions and to establish guidelines.La situación de las bibliotecas especializadas y de los centros de documentación en Cataluña es difícil de definir, ya que hay un considerable desconocimiento sobre qué centros pertenecen a esta categoría y sobre las características que tienen. Es una tipología de centros sobre la que no se ha llevado a cabo ninguna acción institucional como la que llevó a organizar el sistema de lectura pública o las bibliotecas universitarias. Esta cantidad indeterminada de centros, de varias titularidades públicas y privadas, tiene un origen, una historia, unos fondos, unos servicios, unos usuarios y unos objetivos muy diferentes. El retoque se les presenta es la plena integración en el sistema bibliotecario de Cataluña y, para lograrlo, es necesario planificar acciones conjuntas y restablecer las directrices que faciliten que logren los objetivos comunes al sistema bibliotecario

Fuentes de información en etnomusicología: un instrumento auxiliar en el desarrollo de las investigaciones

Comunicación presentada en: V Congreso de la SIbE ( Sociedad de Etnomusicología ), celebrado en Rentería, en marzo de 1999A través de una búsqueda de diferentes términos afines al ámbito de la Etnomusicología en las principales bases de datos bibliográficas y catálogos de las principales bibliotecas se aportan datos para considerar esas fuentes de información como de gran interés para el desarrollo de la investigacíones en ese campo

Cell, tissue and gene products with marketing authorization in 2018 worldwide

Cell and gene therapies (CGTs) are progressively entering into clinical practice in different parts of the world. The International Society for Cell & Gene Therapy (ISCT), a global scientific society, has been committed since 1992 to supporting and developing knowledge on clinical applications of CGTs. Considering the number of products that have been progressively approved and, in some cases, withdrawn in recent years, the ISCT would like to present a brief annual report on CGTs with marketing authorization (MA) in different regions. This article reflects the dynamic momentum around authorized CGTs coinciding with the parallel increase of unproven approaches where cells are delivered without appropriate and rigorous scientific and regulatory assessment and authorization. This is intended to be a living document with a yearly update linked to a dedicated section of the ISCT website for faster adjustments. The aim is to ultimately inform, by periodic snapshots, the scientific community, healthcare stakeholders and patient associations on authorized CGT products as a way to increase communication around the approved therapeutic approaches charged with heightened expectations

The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders' concerns

N/AIn Europe, advanced therapy medicinal products (ATMPs), including cell and gene medicinal products , tissue-engineered products and combined ATMPs, are governed by Directive 2001/ 83/EC and Regulation 726/2004, amended by Regulation 1394/2007, which sets specific rules concerning their centralized marketing authorization (MA), supervision and pharmacovigilance. Nevertheless, ATMPs not intended to be marketed and not industrially prepared are beyond the scope of Directive 2001/83/EC, according to article 28 of Regulation 1394/2007. This is commonly called “hospital exemption” (HE) and is restricted to any ATMP “which is prepared on a non-routine basis according to specific quality standards, and used within the same Member State in a hospital under the exclusive professional responsibility of amedical practitioner, in order to comply with an individual medical prescription for a custom-made product for an individual patient.” Member States must ensure that the manufacture of ATMPs under HE is authorized by the competent national authority and that traceability, pharmacovigilance and specific quality standards are equivalent to those applying to ATMPs granted centralized MA

Part 1: Defining unproven cellular therapies

Given the potential of cell-based products, including stem/progenitor cells and immune cells, there is a global effort to introduce these therapies into the clinic to correct organ dysfunctions, to treat cancer and to abrogate autoimmune diseases and a wide variety of pathological conditions [1–3]. Relatively easy access to these cells, obtained from marrow, adipose, cord blood and other human tissues, provides tremendous opportunity for translational research, particularly for indications with no satisfactory medical solution for patients with “unmet medical needs.” Prenatal and adult stem cells (including induced pluripotent stem cells have significant potential to rebuild tissues and correct dysfunctional organs in human diseases

Both baseline clinical factors and genetic polymorphisms influence the development of severe functional status in ankylosing spondylitis

Functional severity in ankylosing spondylitis (AS) patients is variable and difficult to predict early. The aim of our study was to assess whether a combination of baseline clinical factors and genetic markers may predict the development of severe functional status in AS. We performed a cross-sectional association study on AS patients included in the Spanish National Registry of Spondyloarthropathies-REGISPONSER. Bath Ankylosing Spondylitis Functional Index (BASFI) was standardized by adjusting for disease duration since the first symptoms (BASFI/t). We considered as severe functional status the values of BASFI/t in the top of the 60th (p60), 65th (p65), 70th (p70), and 75th (p75) percentile. We selected 384 single nucleotide polymorphisms (SNPs) distributed in 190 genes to be analyzed. The study cohort included 456 patients with mean age 50.8(±10.5) years and with mean disease duration since first symptoms 24.7 (±10.1) years. Older age at disease onset and neck pain at baseline showed statistical significant association with severe BASFI/t. Polymorphisms associated in the allele frequencies test with severe BASFI/t in all classifications were: rs2542151 (p60 [P =.04], p65 [P =.04], p70 [P =.001] and p75 [P =.001]) and rs2254441 (p60 [P =.004], p65 [P =.02], p70 [P =.01] and p75 [P<.001]). Genotype association, after adjustment for covariates, found an association in three of the four patients' classifications for rs2542151 and in two of the classifications for rs2254441.Forward logistic regression did not identify any model with a good predictive power for severe functional development. In our study we identified clinical factors and 24 polymorphisms associated with development of severe functional status in AS patients. Validation of these results in other cohorts is requiredThis work was supported by the Ministerio de Ciencia e Innovación of Spain [Proyect PSE-01000-2006-1] and by Progenika Biopharma S.

Part 2: Making the "unproven" "proven"

n/